- Home
- ENTX vs ARMP Comparison
ENTX vs ARMP Comparison
Compare ENTX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- ARMP
- Stock Information
- Founded
- ENTX 2010
- ARMP N/A
- Country
- ENTX Israel
- ARMP United States
- Employees
- ENTX N/A
- ARMP N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTX Health Care
- ARMP Health Care
- Exchange
- ENTX Nasdaq
- ARMP Nasdaq
- Market Cap
- ENTX 67.2M
- ARMP 80.0M
- IPO Year
- ENTX 2018
- ARMP N/A
- Fundamental
- Price
- ENTX $2.25
- ARMP $2.00
- Analyst Decision
- ENTX Strong Buy
- ARMP Strong Buy
- Analyst Count
- ENTX 1
- ARMP 1
- Target Price
- ENTX $10.00
- ARMP $7.00
- AVG Volume (30 Days)
- ENTX 54.3K
- ARMP 9.2K
- Earning Date
- ENTX 11-08-2024
- ARMP 11-13-2024
- Dividend Yield
- ENTX N/A
- ARMP N/A
- EPS Growth
- ENTX N/A
- ARMP N/A
- EPS
- ENTX N/A
- ARMP N/A
- Revenue
- ENTX $99,000.00
- ARMP $5,467,000.00
- Revenue This Year
- ENTX N/A
- ARMP N/A
- Revenue Next Year
- ENTX N/A
- ARMP $83.33
- P/E Ratio
- ENTX N/A
- ARMP N/A
- Revenue Growth
- ENTX 607.14
- ARMP 34.92
- 52 Week Low
- ENTX $0.52
- ARMP $1.97
- 52 Week High
- ENTX $3.35
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- ENTX 68.35
- ARMP 38.26
- Support Level
- ENTX $2.02
- ARMP $1.97
- Resistance Level
- ENTX $2.28
- ARMP $2.30
- Average True Range (ATR)
- ENTX 0.17
- ARMP 0.11
- MACD
- ENTX 0.04
- ARMP -0.02
- Stochastic Oscillator
- ENTX 77.01
- ARMP 7.50
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.